After graduating from the University of Tennessee's College of Pharmacy in 2001 as a nuclear authorized user with his Pharm.D degree, Dr. Fred Gattas began his career as a staff pharmacist with the Mallinckrodt pharmacy in Memphis. It was there that he obtained his BPS Board Certification in Nuclear Pharmacy and was designated Radiation Safety Officer. In 2006 Dr. Gattas was promoted to Sr. Quality Assurance Associate for Mallinckrodt Inc., relocating to St. Louis to take on responsibility for the company’s continuing quality improvement program and all clinical nuclear pharmacy support. In 2015, Dr. Gattas was named a Fellow of the American Pharmacists Association. After serving as the Senior Director for Quality and Safety with Triad Isotopes, Inc., which merged its nuclear pharmacy operations with Mallinckrodt (then Covidien) in 2010, he transitioned to Curium where he is in charge of North America’s Pharmacovigilance and Product Monitoring.
Dr. Gattas also trains future generations of nuclear pharmacists as an assistant professor for the University of Tennessee Health Science Center, Southern Illinois University-Edwardsville, and the St. Louis College of Pharmacy. In addition, he has served as the New Practitioner Officer for the APhA-APPM Nuclear Section; as chair of the APhA-APPM New Practitioner Network; as chair for the Tennessee Pharmacist Association’s Pharmacist Society; as chair of the BPS Nuclear Specialty Council; and as Chair for the Nuclear Section of APhA-APPM. He remains active in the profession as a member of APhA, and the Society of Nuclear Medicine and Molecular Imaging, in addition to the Missouri state pharmacy association. Dr. Gattas is also a member of the Board of Governors for St. Jude Children’s Research Hospital.